Regulatory approval

Published by the Health Canada. Approved

Health Canada approved trametinib in combination with dabrafenib for the adjuvant treatment of patients with BRAF V600E or V600K-mutant melanoma and lymph node involvement after complete resection.

This is written in the approval document as:

MEKINIST (trametinib), in combination with dabrafenib, is indicated for the adjuvant treatment of patients with melanoma with a BRAF V600 mutation and involvement of lymph nodes, following complete resection.

Citation

Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00083524.PDF. Revised February 2026. Accessed April 2026.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies

Contributions

Date	Contributor	Description